Targeting Nerve Growth Factor for Pain Management in Osteoarthritis—Clinical Efficacy and Safety

Brett W. Dietz, Mary C. Nakamura, Matthew T. Bell, Nancy E. Lane

Research output: Contribution to journalReview articlepeer-review

Abstract

Nerve growth factor (NGF) is a neurotrophin that mediates pain sensitization in pathologic states, including osteoarthritis. In clinical trials, antibodies to NGF reduce pain and improve physical function due to osteoarthritis of the knee or hip and have a long duration of action. Rapidly progressive osteoarthritis is a dose-dependent adverse event with these agents, and additional joint safety signals, such as subchondral insufficiency fractures and increased rates of total joint replacement, are reported. The effects on pain and potential mechanisms behind these joint events both are of considerable importance in the consideration of future use of anti-NGF therapies for osteoarthritis.

Original languageEnglish (US)
JournalRheumatic Disease Clinics of North America
DOIs
StateAccepted/In press - 2021

Keywords

  • Anti-NGF
  • Nerve growth factor
  • NGF
  • Osteoarthritis
  • Pain
  • Review

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Targeting Nerve Growth Factor for Pain Management in Osteoarthritis—Clinical Efficacy and Safety'. Together they form a unique fingerprint.

Cite this